Hedge fund Cannell Capital acquires 13% stake in Nueronetics
Activist hedge fund Cannell Capital has acquired close to a 13% stake in medical device company Neuronetics, according to a report by the Philadelphia Business Journal, and is now seeking a seat on the company’s board.